期刊
TOXICOLOGY AND APPLIED PHARMACOLOGY
卷 368, 期 -, 页码 49-54出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.taap.2019.02.009
关键词
NAFLD; NASH models; Folate receptor-beta; Macrophages; Imaging
资金
- National Institutes of Health [N01-DK-7-0004/HHSN267200700004C]
Introduction: Nonalcoholic steatohepatitis (NASH) afflicts 20-36% of individuals with nonalcoholic fatty liver disease (NAFLD). A lipotoxic hepatic environment, altered innate immune signaling and inflammation are defining features of progression to NASH. Activated resident liver macrophages express folate receptor beta (FR-beta) which may be an indicator of progression from steatosis to NASH. The goals of this study were to characterize FR-beta protein expression in human NAFLD and rodent models of NASH, and demonstrate liver targeting of an FR-beta imaging agent to the liver of a rodent NASH model using FR-beta. Methods: Rat liver lysates from methionine choline deficient (MCD) fed rats, high fat diet (HFD) and methionine choline sufficient (MC+) rat controls were analyzed for hepatic FR-beta protein. The FR-beta-targeted agent, Etarfolatide was injected into MCD and MC + -fed C57BL/6 mice for efficient FastSPECT hepatic imaging. Additionally, FR-beta expression across the stages of human NAFLD from normal to NASH was assessed. Results: FastSPECT images show targeting of Etarfolatide to the liver of mice fed 8 weeks of MCD diet but not control-fed mice. The MCD rat model exhibited significantly increased protein expression of hepatic FR-beta in contrast to HFD or normal samples. Similarly human liver samples categorized as NASH Fatty or NASH Not Fatty showed elevated FR-beta protein when compared to normal liver. FR-beta transcript expression levels were elevated across both NASH Fatty and NASH Not Fatty samples. Conclusion: The findings in this study indicate that FR-beta expression in NASH may be harnessed to target agents directly to the liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据